000			02006 a2200553 4500
005			20250513073454.0
264		0	_c19930916
008			199309s 0 0 eng d
022			_a0008-543X
024	7		_a10.1002/1097-0142(19930901)72:5<1733::aid-cncr2820720537>3.0.co;2-x _2doi
040			_aNLM _beng _cNLM
100	1		_aBergmann, L
245	0	0	_aDaily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study. _h[electronic resource]
260			_bCancer _cSep 1993
300			_a1733-42 p. _bdigital
500			_aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aCarcinoma, Renal Cell _xblood
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Combinations
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInfusions, Intravenous
650	0	4	_aInterferon alpha-2
650	0	4	_aInterferon-alpha _xadministration & dosage
650	0	4	_aInterferon-gamma _xblood
650	0	4	_aInterleukin-2 _xadministration & dosage
650	0	4	_aInterleukin-6 _xblood
650	0	4	_aKidney Neoplasms _xblood
650	0	4	_aLeukocyte Count
650	0	4	_aLymphocyte Subsets _xpathology
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Recurrence, Local _xtherapy
650	0	4	_aReceptors, Interleukin-2 _xanalysis
650	0	4	_aRecombinant Proteins
650	0	4	_aRemission Induction
650	0	4	_aT-Lymphocyte Subsets _xpathology
650	0	4	_aTumor Necrosis Factor-alpha _xanalysis
700	1		_aFenchel, K
700	1		_aWeidmann, E
700	1		_aEnzinger, H M
700	1		_aJahn, B
700	1		_aJonas, D
700	1		_aMitrou, P S
773	0		_tCancer _gvol. 72 _gno. 5 _gp. 1733-42
856	4	0	_uhttps://doi.org/10.1002/1097-0142(19930901)72:5<1733::aid-cncr2820720537>3.0.co;2-x _zAvailable from publisher's website
999			_c8347778 _d8347778